Cagrilintide: The Long-Acting Amylin Analogue for Appetite Control Research

What is Cagrilintide?

Cagrilintide is a synthetic analogue of the human hormone **Amylin**. Amylin is naturally co-secreted with insulin by the pancreas in response to food intake. While insulin manages blood sugar, amylin manages the "feeling of fullness." Cagrilintide was engineered with a fatty-acid side chain that allows it to remain active in the body for an entire week, compared to natural amylin which lasts only minutes.

In the REDEFINE clinical trial program, Cagrilintide has demonstrated significant weight-loss efficacy, positioning it as one of the most promising candidates for next-generation metabolic research.

Mechanism: Amylin vs. GLP-1

Most popular weight loss peptides (like Semaglutide) target the GLP-1 receptor. Cagrilintide targets a different pathway entirely:

• Satiety Signaling: It binds to amylin receptors in the **Area Postrema** of the brain, sending a powerful signal that the body has had enough food.
• Gastric Emptying: Like GLP-1, it slows down the rate at which food leaves the stomach, but it does so via a distinct neurological mechanism.
• Glucagon Control: It inhibits the inappropriate release of glucagon after meals, helping to prevent blood sugar spikes.

The "CagriSema" Synergy

The most exciting area of research is the combination of Cagrilintide and Semaglutide (known as CagriSema). Because they target two different satiety pathways, they work synergistically. Research subjects on the combination therapy have shown weight loss exceeding **20% to 25%**, which is significantly higher than either peptide can achieve on its own.

Clinical Research Results

In Phase 2 trials, subjects receiving a 2.4 mg weekly dose of Cagrilintide monotherapy achieved an average weight loss of **10.8%** over 26 weeks, compared to just 3.0% for the placebo group. The safety profile was noted as consistent with other metabolic peptides, with no major unexpected adverse events.

Research Protocols & Dosing

• Administration: Once-weekly subcutaneous injection.
• Starting Research Dose: 0.3 mg per week.
• Maintenance Dose: 2.4 mg per week (titrated over 16-20 weeks).
• Side Effects: Primarily nausea, vomiting, or diarrhea during the escalation phase.
• Storage: Lyophilized powder in the freezer. Reconstituted solution in the refrigerator.

Frequently Asked Questions